Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)
ID: 348732Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Jun 15, 2023 12:00 AM
  4. 4
    Due Sep 7, 2026 12:00 AM
Description

The National Institutes of Health (NIH) has posted a grant opportunity titled "Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)". This grant aims to support doctoral candidates from various academic disciplines for up to two years to complete their doctoral dissertation research project. The research projects should align with NIDA funding priorities and the NIDA Strategic Plan. The goal of this award is to enhance the pool of highly talented researchers in the field of substance use/substance use disorder (SU(D)) research. The NIH encourages applications from individuals who can contribute to diversifying the research workforce. The grant does not require cost sharing or matching. The eligible applicants include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. Non-domestic (non-U.S.) Entities (Foreign Institutions) and non-U.S. components of U.S. Organizations are not eligible to apply. The grant opportunity will close on September 7, 2026. For more information and to apply, visit the following link: http://grants.nih.gov/grants/guide/pa-files/PAR-23-194.html. For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

Point(s) of Contact
Files
Title
Posted
Similar Opportunities
Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)". This grant aims to support clinical research projects that focus on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD) and fundamental brain function relevant to substance use. The grant utilizes a R61/R33 Phased Innovation Award mechanism and is particularly designed to support exploratory and developmental projects that require budgets exceeding those allowed for the R21 mechanism. The grant does not require cost sharing or matching. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The closing date for this grant opportunity is May 7, 2026. For more information and to apply, please visit the following link: [Exploratory Clinical Neuroscience Research on Substance Use Disorders Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-23-157.html). For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.
Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)
Active
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)". This grant aims to support clinical research projects that are exploratory and developmental in nature, focusing on understanding the neurobiological mechanisms underlying Substance Use Disorders (SUD). The grant is particularly designed to support projects that require budgets exceeding those allowed for the R21 mechanism (Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional)). The grant does not require cost sharing or matching requirements. The funding instrument type is a grant, and the category of funding activity is health. The opportunity is posted under the discretionary category and falls under CFDA number 93.279. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), non-domestic (non-U.S.) entities (Foreign Organizations), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The opportunity will close on May 7, 2026, and the last updated date was on June 7, 2023. For more information and to apply, please visit the following link: [Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)](http://grants.nih.gov/grants/guide/pa-files/PAR-23-158.html). For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.
Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)". This funding opportunity aims to accelerate the development of medication for the treatment of Substance Use Disorders (SUDs) by supporting a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have a high impact and quickly yield the necessary results to advance medications closer to FDA approval. The funding will be in the form of short-term (up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code. Eligible applicants include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The grant has a closing date of September 1, 2025, and an award ceiling of $5,000,000. For more information and to apply, visit the following link: [Grant Opportunity Details](https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics (U54 Clinical Trials Not Allowed)
Active
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics (U54 Clinical Trials Not Allowed)". This grant aims to address the lack of early translational funding and technical support for new product developers in the field of substance use disorder (SUD) pharmacotherapeutics. The grant seeks to establish a technical development center (or centers) that will provide researchers with the necessary support to move their ideas beyond the conceptual stage and into product development. This support includes assistance in target product profile development, clinical need assessment, project plan development, prototype development, proof-of-concept study design, preliminary safety assessments, and guidance on current and future regulatory requirements. The funding instrument for this grant is a Cooperative Agreement, and there is no cost sharing or matching requirement. The grant falls under the category of Health and is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments, non-domestic entities (foreign organizations), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territories or Possessions. The closing date for this grant opportunity is November 13, 2024. The maximum award ceiling is $1,900,000. For more information and to apply, interested parties can visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-056.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-056.html). For any inquiries, the contact email is grantsinfo@nih.gov.
NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)
Active
National Institutes of Health
The National Institutes of Health (NIH) is offering the NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research. This grant opportunity aims to support intensive supervised research training and career development experiences for clinician scientists (Scholars) in the field of substance use and substance use disorder research. The program is designed to help Scholars achieve research independence in this area. The maximum award ceiling for this grant is $750,000. The deadline for applications is November 13, 2026. For more information and to apply, please visit the following link: [NIDA Mentored Clinical Scientist Development Program Award](http://grants.nih.gov/grants/guide/pa-files/PAR-24-089.html). For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.